Roschier represented RV Invest and Johnson & Johnson Innovation – JJDC, Inc in a EUR 30 million financing round of Asgard Therapeutics
Recent work|March 20, 2024
Roschier represented RV Invest and Johnson & Johnson Innovation – JJDC, Inc in a financing round of Asgard Therapeutics AB, a Swedish biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy.
RV Invest and Johnson & Johnson Innovation – JJDC, Inc co-led the financing round that also involved participation from the existing investors Novo Holdings, Boehringer Ingelheim Venture Fund, and Industrifonden.
Roschier’s core advisory team comprised Markus Olsson, John Park, Alexis Hekmatfar and Felicia Torstensson.